Zobrazeno 1 - 4
of 4
pro vyhledávání: '"James M. Granfortuna"'
Publikováno v:
Journal of Pharmacy Practice. 31:462-468
Background: Best practice recommendations are lacking. Thus far, literature has described pharmacist-led DOAC monitoring. Objective: The purpose of this study is to describe a DOAC monitoring program involving pharmacy students. Methods: This was an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3283bac6f90ceabdbb07ecf3ca2f951
https://doi.org/10.1177/0897190017752713
https://doi.org/10.1177/0897190017752713
Autor:
Arlan J. Gottlieb, Harold V. Lamberson, Jack Goldberg, Michael E. Theodorakis, Kenneth W. Zamkoff, James M. Granfortuna, J. Robert Smith, Anthony J. Scalzo, Jonathan B. Blitzer, Stephen A. Landaw
Publikováno v:
American journal of hematology. 24(4)
Twenty-one episodes of thrombotic thrombocytopenic purpura (TTP) were treated with plasmapheresis. Adjunctive agents included corticosteroids, aspirin, dipyridamole, and vincristine. There were 17 patients; 12 were female. The median age was 41 years
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::346c8e8b36bfebf7188f936ed483bd29
https://pubmed.ncbi.nlm.nih.gov/3565371
https://pubmed.ncbi.nlm.nih.gov/3565371
Publikováno v:
American journal of hematology. 23(1)
End organ failure in sickle cell disease has classically been attributed to changes in the microvasculature. A case is reported in which sudden and complete loss of blood flow to the left kidney occurred during a painful crisis in a woman with homozy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c4275c480a2598317fcab09a3500cd4
https://pubmed.ncbi.nlm.nih.gov/3740053
https://pubmed.ncbi.nlm.nih.gov/3740053
Autor:
John J. Gullo, Nancy Newman, Bernard J. Poiesz, Sandra J. Ginsberg, Arthur Louie, James M. Granfortuna, Robert L. Comis
Publikováno v:
American journal of clinical oncology. 12(4)
Eighteen patients with previously treated extensive small-cell carcinoma of the lung were entered into a Phase II study employing iproplatin (CHIP), a cis-platin analog. Patients had received a mean of two prior chemotherapeutic regimens. Fifty-five
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc4abdb2852ed223e3126dd9d7c444a1
https://pubmed.ncbi.nlm.nih.gov/2547306
https://pubmed.ncbi.nlm.nih.gov/2547306